A month with Medtrum’s A6 CGM
Is Hba1C a poor yardstick for determining access to new T1D treatments in the real world
Rise of the Machines – Technology and “patient-driven” innovation in the treatment #T1DRoM
Fiasp – going off-label. Attempting to handle the unwanted side effects and retain the rapid effectiveness